These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12712081)

  • 1. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment.
    Pearlstein T; Joliat MJ; Brown EB; Miner CM
    Am J Obstet Gynecol; 2003 Apr; 188(4):887-95. PubMed ID: 12712081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.
    Cohen LS; Miner C; Brown EW; Freeman E; Halbreich U; Sundell K; McCray S
    Obstet Gynecol; 2002 Sep; 100(3):435-44. PubMed ID: 12220761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
    Halbreich U; Bergeron R; Yonkers KA; Freeman E; Stout AL; Cohen L
    Obstet Gynecol; 2002 Dec; 100(6):1219-29. PubMed ID: 12468166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS; Soares CN; Lyster A; Cassano P; Brandes M; Leblanc GA
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.
    Steiner M; Romano SJ; Babcock S; Dillon J; Shuler C; Berger C; Carter D; Reid R; Stewart D; Steinberg S; Judge R
    BJOG; 2001 May; 108(5):462-8. PubMed ID: 11368130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.
    Freeman EW; Sondheimer SJ; Sammel MD; Ferdousi T; Lin H
    J Clin Psychiatry; 2005 Jun; 66(6):769-73. PubMed ID: 15960573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
    Pearlstein T; Yonkers KA
    Expert Opin Pharmacother; 2002 Jul; 3(7):979-91. PubMed ID: 12083997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.
    Steiner M; Steinberg S; Stewart D; Carter D; Berger C; Reid R; Grover D; Streiner D
    N Engl J Med; 1995 Jun; 332(23):1529-34. PubMed ID: 7739706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder.
    Steiner M; Brown E; Trzepacz P; Dillon J; Berger C; Carter D; Reid R; Stewart D
    Arch Womens Ment Health; 2003 Feb; 6(1):71-7. PubMed ID: 12715267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
    Pearlstein TB; Stone AB; Lund SA; Scheft H; Zlotnick C; Brown WA
    J Clin Psychopharmacol; 1997 Aug; 17(4):261-6. PubMed ID: 9241004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
    Yonkers KA; Halbreich U; Freeman E; Brown C; Endicott J; Frank E; Parry B; Pearlstein T; Severino S; Stout A; Stone A; Harrison W
    JAMA; 1997 Sep; 278(12):983-8. PubMed ID: 9307345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
    Romano S; Judge R; Dillon J; Shuler C; Sundell K
    Clin Ther; 1999 Apr; 21(4):615-33; discussion 613. PubMed ID: 10363729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series.
    Ravindran LN; Woods SA; Steiner M; Ravindran AV
    Arch Womens Ment Health; 2007; 10(3):125-7. PubMed ID: 17431739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine in the treatment of premenstrual dysphoric disorder.
    Carr RR; Ensom MH
    Ann Pharmacother; 2002 Apr; 36(4):713-7. PubMed ID: 11918525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential time course efficacy on dysphoric and physical symptoms of the intermittent dosing of fluoxetine in the premenstrual dysphoric disorder.
    Tamayo JM; Gómez G; Barrios R; Holguín J; Adrianzén C
    J Clin Psychopharmacol; 2004 Aug; 24(4):469-71. PubMed ID: 15232351
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluoxetine in the treatment of premenstrual dysphoria.
    Su TP; Schmidt PJ; Danaceau MA; Tobin MB; Rosenstein DL; Murphy DL; Rubinow DR
    Neuropsychopharmacology; 1997 May; 16(5):346-56. PubMed ID: 9109106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine in the treatment of late luteal phase dysphoric disorder.
    Stone AB; Pearlstein TB; Brown WA
    J Clin Psychiatry; 1991 Jul; 52(7):290-3. PubMed ID: 2071558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low doses of fluoxetine for the treatment of emotional premenstrual syndrome: a randomized double-blind, placebo-controlled, pilot study.
    Maranho MCMF; Guapo VG; de Rezende MG; Vieira CS; Brandão ML; Graeff FG; Lovick T; Del-Ben CM
    Psychoneuroendocrinology; 2023 Nov; 157():106360. PubMed ID: 37572412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.